Azilsartan Medoxomil: A New Angiotensin Receptor Blocker
Authors:
- Judy W.M. ChengJCJudy W.M. Cheng
- 1 November 2011
- journal article
- review article
- Published by Elsevier in Clinical Therapeutics
- Vol. 33 (11) , 1577-1589
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure MonitoringThe Journal of Clinical Hypertension, 2011
- Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 HypertensionHypertension, 2011
- In Vitro Antagonistic Properties of a New Angiotensin Type 1 Receptor Blocker, Azilsartan, in Receptor Binding and Function StudiesThe Journal of Pharmacology and Experimental Therapeutics, 2011
- The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood PressureThe Journal of Clinical Hypertension, 2011
- Efficacy of Angiotensin Receptor Blockers in Cardiovascular DiseaseCardiovascular Drugs and Therapy, 2006
- Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic reviewBMJ, 2004
- Angiotensin‐Converting Enzyme Inhibitors and Stroke Risk: Benefit Beyond Blood Pressure Reduction?Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2004
- Essential hypertensionThe Lancet, 2003
- Original Papers. Success and Predictors of Blood Pressure Control in Diverse North American Settings: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)The Journal of Clinical Hypertension, 2002
- Baseline Characteristics and Early Blood Pressure Control in the CONVINCE TrialHypertension, 2001